Prentiss Smith & CO Inc Regeneron Pharmaceuticals, Inc. Transaction History
Prentiss Smith & CO Inc
- $142 Million
- Q1 2025
A detailed history of Prentiss Smith & CO Inc transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Prentiss Smith & CO Inc holds 2,110 shares of REGN stock, worth $1.18 Million. This represents 0.94% of its overall portfolio holdings.
Number of Shares
2,110
Previous 2,035
3.69%
Holding current value
$1.18 Million
Previous $1.45 Million
7.66%
% of portfolio
0.94%
Previous 1.01%
Shares
31 transactions
Others Institutions Holding REGN
# of Institutions
1,496Shares Held
87.1MCall Options Held
1.53MPut Options Held
1.44M-
Vanguard Group Inc Valley Forge, PA9.29MShares$5.21 Billion0.12% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$4.74 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.06MShares$3.96 Billion0.41% of portfolio
-
State Street Corp Boston, MA4.83MShares$2.71 Billion0.14% of portfolio
-
Capital International Investors Los Angeles, CA4.74MShares$2.66 Billion0.66% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $60.2B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...